Your browser doesn't support javascript.
loading
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Neuen, Brendon L; Oshima, Megumi; Agarwal, Rajiv; Arnott, Clare; Cherney, David Z; Edwards, Robert; Langkilde, Anna Maria; Mahaffey, Kenneth W; McGuire, Darren K; Neal, Bruce; Perkovic, Vlado; Pong, Annpey; Sabatine, Marc S; Raz, Itamar; Toyama, Tadashi; Wanner, Christoph; Wheeler, David C; Wiviott, Stephen D; Zinman, Bernard; Heerspink, Hiddo J L.
Afiliación
  • Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., C.A.).
  • Oshima M; Department of Nephrology and Laboratory Medicine, Kanazawa University, Japan (M.O., T.T.).
  • Agarwal R; Indiana University School of Medicine and VA Medical Center, Indianapolis (R.A.).
  • Arnott C; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., C.A.).
  • Cherney DZ; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia (C.A.).
  • Edwards R; Sydney Medical School, University of Sydney, Australia (C.A.).
  • Langkilde AM; Department of Medicine and Department of Physiology, Division of Nephrology, University Health Network, University of Toronto, Ontario, Canada (D.Z.C.).
  • Mahaffey KW; Janssen Research & Development, LLC, Raritan, NJ (R.E.).
  • McGuire DK; AstraZeneca, Gothenburg, Sweden (A.M.L.).
  • Neal B; Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.W.M.).
  • Perkovic V; Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas (D.K.M.).
  • Pong A; The Charles Perkins Centre, University of Sydney, Australia (B.N.).
  • Sabatine MS; Department of Epidemiology and Biostatistics, Imperial College London, UK (B.N.).
  • Raz I; Faculty of Medicine, University of New South Wales, Sydney, Australia (V.P.).
  • Toyama T; Merck & Co Inc, Kenilworth, NJ (A.P.).
  • Wanner C; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (M.S.S., S.D.W.).
  • Wheeler DC; Diabetes Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel (I.R.).
  • Zinman B; Division of Nephrology, Department of Medicine, Würzburg University Clinic, Germany (C.W.).
  • Heerspink HJL; Department of Renal Medicine, UCL Medical School, London, UK (D.C.W.).
Circulation ; 145(19): 1460-1470, 2022 05 10.
Article en En | MEDLINE | ID: mdl-35394821
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Insuficiencia Renal Crónica / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Hiperpotasemia / Hipopotasemia Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: Circulation Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Insuficiencia Renal Crónica / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Hiperpotasemia / Hipopotasemia Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: Circulation Año: 2022 Tipo del documento: Article